New RT PCR Fl SC2 Covid-19 Flu & Covid Test Just As Unsuitable for Virus Detection as Original Test

Updated: Aug 16, 2021


Public health organizations continue to recommend and 'emergency approve' testing unsuitable for diagnosis of Covid-19 infections as documented by agency's own data, and international peer review. Media 'fact checkers' are covering up significant and extensive evidence of severe testing issues and allowing the CDC to make claims actively contradicted by organization's own evidence.

Media Fact Checkers: Who Funds them?


Dr Sam Bailey Explains Problems with 'New' Test:


Please go HERE for extensive documentation on SEVERE flaws with the RT PCR Test from government health organization data and international panel peer review. Companion article to this piece:


CDC: PCR Covid-19 'Gold Standard' Test to Be Discontinued, Replaced With Equally Flawed Testing


The new Covid-19 test which the CDC will institute for detection of Sars CoV-2 (as it phase out the the RT PCR Diagnostic Panel) is the Emergency Use Approved Only: CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay


The new testing is based on the same scientific paper currently under review for retraction per request of the International Consortium of Science peer review panel of 22 relevant experts:


Retraction request letter to Eurosurveillance editorial board


The panel found ten severe errors and deemed RT PCR testing 'useless' for detection of Sars CoV'2, the virus attributed to cause Covid-19 infection.


The CDC employed the original RT PCR testing to evaluate clinical effectiveness. On this one parameter, the CDC has completely invalidated this new test's validity as RT PCR Diagnostic Panel has been extensively documented to be unsuitable for detection of Sars CoV2. No research conducted with testing unsuitable for detection of virus employed to study has any clinical validity. This has rendered all data and research (including vaccine trials) employing this testing as invalid, a central point.


Clinical Evaluation:


Clinical performance of the SARS-CoV-2 Influenza Multiples Assay was evaluated using a panel of upper and lower respiratory, residual human clinical specimens. A total of 104 positive specimens (33 SARS-CoV-2 positive, 30 influenza A positive, 30 influenza B positive) and 11 negative specimens were extracted using the QIAGEN EZ1 Advanced XL with the QIAGEN EZ1 DSP Virus kit. Extracted samples were tested using the Flu SC2 Multiplex Assay with both the Applied Biosystems TaqPathTM Multiplex Master Mix (No ROX) and the Quantabio UltraPlexTM 1-Step ToughMix® (4X). SARS-CoV-2 positive specimens were confirmed using the FDA-authorized CDC 2019-nCoV-Real-Time RT-PCR Diagnostic Panel, and Influenza A and B virus positive specimens (NP/OP) were confirmed using the FDA-cleared CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel Influenza A/B Typing Kit. Specimens negative for SARS-CoV-2, influenza A virus and influenza B virus were confirmed by negative result(s) on both the CDC 2019-nCoV-Real-Time RT-PCR Diagnostic Panel and the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel Influenza A/B Typing Kit. All controls performed as expected and a summary of the results is presented in Table 27.


(Additionally, this sample size is so small as to be meaningless)


RT PCR testing can not determine if RNA originates from a virus. Test picks up dead non-infectious material and live material, it is non-specific to Sars CoV2. The CDC admits in the Emergency Use guidelines detection of RNA does NOT equate to definitive presence of infectious virus (page 33):


  • Detection of viral RNA may not indicate the presence of infectious virus or that influenza or SARS- CoV-2 viruses are the causative agent for clinical symptoms.

  • The performance of this test has not been established for monitoring treatment of influenza A, influenza B, or SARS-CoV-2 infection.

  • The performance of this assay has not been established for screening of blood or blood products for the presence of influenza A, influenza B or SARS-CoV-2.

  • This assay cannot rule out diseases caused by other bacterial or viral pathogens.


Sars CoV2 isolation sequencing is based on patented partial gene sequences with patent dates which predate the 2020 Covid-19 attributed pandemic.


Full video of interview of David Martin with Reiner Fuellmich on patent dates for Sars CoV2 sequencing utilized in Covid-19 testing, research, and product development:


The virus has not been documented to have been isolated from a purified specimen originating from a infected human sample. Research isolation studies for Sars CoV2 employed RNA & existing cell lines in isolation procedures (note, individuals investigating proper isolation protocols are NOT questioning isolation studies were undergone, rather the scientific methods utilized within the studies, its called 'peer review', a process citizens should welcome and laud:


Researchers engaged in verifying appropriate isolation & sequencing through documentation request have returned over 80 Freedom of Information Act requests stating 'documentation does not exist:


Freedom of Information Act Requests Documents HERE


Over 280 Covid-19 different test kits and devices have been recalled, as of this date. This constitutes FDA recall of TENS OF MILLIONS of tests at a cost of billions of dollars, none of which have any validity for informing Covid-19 diagnosis due to severe flaws and contamination issues. Another 11 tests were recalled just this week.


Immediate correction of all case data generated from faulty testing should immediately ensue, and a complete halt to all testing needs to be immediately implemented. There are significant health risk as documented by the CDC with a false positive result, and the continual monthly recall of millions of unsuitable (often contaminated tests) must not be allowed to continue unabated:


Per CDC:


"In the event of a false positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close


contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 patients, limits in the ability to work, delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.".


CDC FACT SHEET FOR HEALTHCARE PROVIDERS


Full documentation with links to FDA recall source list may be viewed in this post:


Contaminated Covid-19 Tests, Millions Removed from Market, Implicated in India Black Fungal Outbreak


Important companion articles:


Evidence Indicates CDC Manipulating Covid-19 PCR Testing, Provide False Evidence of Vaccine Efficacy


On Virus Isolation Method, Non-Specific Covid-19 Tests, New Drug Treatments for Covid-19 Infections



1,162 views0 comments